- Home
- PRQR vs TRVI Comparison
PRQR vs TRVI Comparison
Compare PRQR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- TRVI
- Stock Information
- Founded
- PRQR 2012
- TRVI 2011
- Country
- PRQR Netherlands
- TRVI United States
- Employees
- PRQR N/A
- TRVI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- TRVI Health Care
- Exchange
- PRQR Nasdaq
- TRVI Nasdaq
- Market Cap
- PRQR 309.5M
- TRVI 383.4M
- IPO Year
- PRQR 2014
- TRVI 2019
- Fundamental
- Price
- PRQR $1.74
- TRVI $6.29
- Analyst Decision
- PRQR Strong Buy
- TRVI Strong Buy
- Analyst Count
- PRQR 6
- TRVI 8
- Target Price
- PRQR $8.17
- TRVI $15.94
- AVG Volume (30 Days)
- PRQR 381.0K
- TRVI 4.1M
- Earning Date
- PRQR 05-08-2025
- TRVI 05-06-2025
- Dividend Yield
- PRQR N/A
- TRVI N/A
- EPS Growth
- PRQR N/A
- TRVI N/A
- EPS
- PRQR N/A
- TRVI N/A
- Revenue
- PRQR $20,235,014.00
- TRVI N/A
- Revenue This Year
- PRQR $210.18
- TRVI N/A
- Revenue Next Year
- PRQR $33.25
- TRVI N/A
- P/E Ratio
- PRQR N/A
- TRVI N/A
- Revenue Growth
- PRQR 306.68
- TRVI N/A
- 52 Week Low
- PRQR $1.61
- TRVI $2.30
- 52 Week High
- PRQR $4.62
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- PRQR 29.14
- TRVI 78.13
- Support Level
- PRQR $1.78
- TRVI $4.24
- Resistance Level
- PRQR $1.87
- TRVI $7.39
- Average True Range (ATR)
- PRQR 0.15
- TRVI 0.50
- MACD
- PRQR -0.05
- TRVI 0.21
- Stochastic Oscillator
- PRQR 2.34
- TRVI 66.67
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.